edaravone oral Radicava ORS
Selected indexed studies
- New Oral Form for ALS Drug. (Am J Nurs, 2022) [PMID:36005791]
- Development and Validation of a Stability-Indicating RP-HPLC Method for Edaravone Quantification. (Molecules, 2025) [PMID:40649379]
- In brief: Edaravone oral suspension (Radicava ORS) for ALS. (Med Lett Drugs Ther, 2022) [PMID:36098666]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Edaravone Oral Suspension: A Neuroprotective Agent to Treat Amyotrophic Lateral Sclerosis. (2024) pubmed
- New Oral Form for ALS Drug. (2022) pubmed
- Development and Validation of a Stability-Indicating RP-HPLC Method for Edaravone Quantification. (2025) pubmed
- In brief: Edaravone oral suspension (Radicava ORS) for ALS. (2022) pubmed